Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters











Database
Language
Publication year range
1.
Catheter Cardiovasc Interv ; 93(7): 1205-1210, 2019 Jun 01.
Article in English | MEDLINE | ID: mdl-31112633

ABSTRACT

BACKGROUND: Acutely decompensated heart failure remains a major clinical problem. Volume overload promotes cardiac and renal dysfunction and is associated with increased morbidity and mortality in heart failure. We hypothesized that transient occlusion of the superior vena cava (SVC) will reduce cardiac filling pressures without reducing cardiac output or systemic blood pressure. The objective of this proof of concept study was to provide initial evidence of safety and feasibility of transient SVC occlusion in patients with acutely decompensated heart failure and reduced ejection fraction. METHODS AND RESULTS: In eight patients with systolic heart failure, SVC occlusion was performed using a commercially available occlusion balloon. Five minutes of SVC occlusion reduced biventricular filling pressures without decreasing systemic blood pressure or total cardiac output. In three of the eight patients, a second 10-minutes occlusion had similar hemodynamic effects. SVC occlusion was well-tolerated without development of new symptoms, new neurologic deficits, or any adverse events including stroke, heart attack, or reported SVC injury or thrombosis at 7 days of follow up. CONCLUSION: We report the first clinical experience with transient SVC occlusion as a potentially new therapeutic approach to rapidly reduce cardiac filling pressures in heart failure. No prohibitive safety signal was identified and further testing to establish the clinical utility of transient SVC occlusion for acute decompensated heart failure is justified.


Subject(s)
Balloon Occlusion , Heart Failure/therapy , Vena Cava, Superior/physiopathology , Ventricular Function, Left , Ventricular Function, Right , Ventricular Pressure , Aged , Balloon Occlusion/adverse effects , Balloon Occlusion/instrumentation , Feasibility Studies , Female , Heart Failure/diagnosis , Heart Failure/physiopathology , Humans , Male , Middle Aged , Proof of Concept Study , Recovery of Function , Stroke Volume , Time Factors , Treatment Outcome , Vascular Access Devices , Vena Cava, Superior/diagnostic imaging
2.
J Vasc Res ; 43(1): 109-19, 2006.
Article in English | MEDLINE | ID: mdl-16340215

ABSTRACT

We hypothesized that prolonged angiotensin II (AngII) infusion would alter vascular reactivity by enhancing superoxide anion (O-.2) generation. Male C57BL/6 mice were infused with AngII at 400 ng/kg/min (n=16, AngII mice) or vehicle (n=16, sham mice) for 2 weeks via subcutaneous osmotic minipumps. Contraction and relaxation of mesenteric resistance vessels (MRVs) were assessed using a Mulvany-Halpern myograph. AngII infusion increased systolic blood pressure, MRV NADPH oxidase activity and expression of p22phox mRNA. Contraction to norepinephrine was unchanged, but AngII infusion increased contractile responses to AngII (41+/-5 vs. 10+/-4%, p<0.001) and endothelin-1 (ET-1; 95+/-10 vs. 70+/-9%, p<0.05), which was normalized by tempol (10(-4) M, a stable membrane-permeable superoxide dismutase mimetic) and ebselen [10(-5) M, a peroxynitrite (ONOO-) scavenger]. Endothelium removal enhanced MRV contraction to AngII and ET-1 in sham mice but blunted these contractile responses in AngII mice. Relaxation to ACh was impaired in AngII mice (60.1+/-8.8 vs. 83.2+/-3.5%, p<0.01), which normalized by tempol, whereas relaxation to sodium nitroprusside was similar in both groups. N-nitro-L-arginine (NNLA, a nitric oxide synthase inhibitor), partially inhibited acetylcholine relaxation of vessels from sham mice but not from AngII mice. The residual endothelium-dependent hyperpolarizing-factor-like relaxation was not different between groups. In conclusion,the AngII slow pressor response in mouse MRVs consisted of specific contractile hyperresponsiveness and impairment in the NO-mediated component of endothelium-dependent relaxation, which was mediated by O-.2 and ONOO- in the vascular smooth muscle cell.


Subject(s)
Angiotensin II/pharmacology , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Superoxides/metabolism , Vasoconstrictor Agents/pharmacology , Animals , Arterioles/drug effects , Arterioles/metabolism , Biological Factors/metabolism , Blood Pressure/drug effects , Endothelium-Dependent Relaxing Factors/metabolism , Hypertension/chemically induced , Hypertension/metabolism , Male , Membrane Transport Proteins/genetics , Mesenteric Arteries/drug effects , Mesenteric Arteries/metabolism , Mice , Mice, Inbred C57BL , NADP/metabolism , NADPH Oxidases/genetics , Nitric Oxide/metabolism , Oxidative Stress/drug effects , Peroxynitrous Acid/pharmacology , Phosphoproteins/genetics , RNA, Messenger/analysis , Vascular Resistance/drug effects , Vasoconstriction/drug effects
3.
Am J Physiol Heart Circ Physiol ; 288(1): H22-8, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15598867

ABSTRACT

We tested the hypothesis that superoxide anion (O(2)(-).) generated in the kidney by prolonged angiotensin II (ANG II) reduces renal cortical Po(2) and the use of O(2) for tubular sodium transport (T(Na):Q(O(2))). Groups (n = 8-11) of rats received angiotensin II (ANG II, 200 ng.kg(-1).min(-1) sc) or vehicle for 2 wk with concurrent infusions of a permeant nitroxide SOD mimetic 4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (Tempol, 200 nmol.kg(-1).min(-1)) or vehicle. Rats were studied under anesthesia with measurements of renal oxygen usage and Po(2) in the cortex and tubules with a glass electrode. Compared with vehicle, ANG II increased mean arterial pressure (107 +/- 4 vs. 146 +/- 6 mmHg; P < 0.001), renal vascular resistance (42 +/- 3 vs. 65 +/- 7 mmHg.ml(-1).min(-1).100 g(-1); P < 0.001), renal cortical NADPH oxidase activity (2.3 +/- 0.2 vs. 3.6 +/- 0.4 nmol O(2)(-)..min(-1).mg(-1) protein; P < 0.05), mRNA and protein expression for p22(phox) (2.1- and 1.8-fold respectively; P < 0.05) and reduced the mRNA for extracellular (EC)-SOD (-1.8 fold; P < 0.05). ANG II reduced the Po(2) in the proximal tubule (39 +/- 1 vs. 34 +/- 2 mmHg; P < 0.05) and throughout the cortex and reduced the T(Na):Q(O(2)) (17 +/- 1 vs. 9 +/- 2 mumol/mumol; P < 0.001). Tempol blunted or prevented all these effects of ANG II. The effects of prolonged ANG II to cause hypertension, renal vasoconstriction, renal cortical hypoxia, and reduced efficiency of O(2) usage for Na(+) transport, activation of NADPH oxidase, increased expression of p22(phox), and reduced expression of EC-SOD can be ascribed to O(2)(-). generation because they are prevented by an SOD mimetic.


Subject(s)
Angiotensin II/pharmacology , Kidney/metabolism , Oxidative Stress/physiology , Oxygen Consumption/drug effects , Angiotensin II/administration & dosage , Angiotensin II/antagonists & inhibitors , Animals , Antioxidants/pharmacology , Cyclic N-Oxides/pharmacology , Drug Administration Schedule , Membrane Transport Proteins/genetics , NADPH Dehydrogenase/genetics , NADPH Oxidases , Oxygen/blood , Partial Pressure , Phosphoproteins/genetics , RNA, Messenger/metabolism , Rats , Rats, Inbred WKY , Renal Circulation/drug effects , Spin Labels , Superoxide Dismutase/genetics , Superoxides/metabolism
4.
Circ Res ; 94(11): 1436-42, 2004 Jun 11.
Article in English | MEDLINE | ID: mdl-15117817

ABSTRACT

We tested the hypothesis that cyclooxygenase (COX), thromboxane A2 synthase (TxA2-S), thromboxane prostanoid receptors (TP-Rs), or superoxide anion (O2-) mediates enhanced contractions of renal afferent arterioles (Aff) of angiotensin II (Ang II)-infused rabbits. Rabbits were infused with vehicle (sham), Ang II 60 ng x kg(-1) x min(-1) (Ang II 60) or 200 ng x kg(-1) x min(-1) (Ang II 200). There was a selective enhanced vasoconstriction of Affs from Ang II 60 rabbits to Ang II (Deltadiameter-78+/-8% versus -43+/-9%; P<0.01) that was normalized by a TP-R antagonist but not by a superoxide dismutase (SOD) mimetic. Affs from Ang II 200 rabbits had increased (P<0.01) mRNA for COX-2 and enhanced vasoconstriction to Ang II, U-46 619 (TP-R mimetic), and endothelin-1 that was normalized by ifetroban plus tempol together. Endothelium removal enhanced Ang II responses of Affs from sham rabbits but blunted responses from Ang II 200 rabbits and abolished responses to ifetroban. Affs from Ang II 200 rabbits had an endothelium-dependent contraction factor (EDCF) response to that was blunted (P<0.001) by a SOD mimetic or antagonists of COX-1 or TxA2-S but normalized by antagonists of COX-2 or TP-R. Thus, enhanced Ang II responses in Affs from rabbits infused with slow pressor Ang II are mediated independently by O2- in the vascular smooth muscle cells and by an EDCF that is principally a vasoconstrictor prostaglandin generated by COX-2 >-1 activating TP-Rs, whereas enhanced responses in rabbits infused with a lower Ang II dose are dependent on TP-R but not O2-.


Subject(s)
8,11,14-Eicosatrienoic Acid/analogs & derivatives , Angiotensin II/pharmacology , Kidney/blood supply , Vasoconstriction/drug effects , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , 8,11,14-Eicosatrienoic Acid/pharmacology , Angiotensin II/administration & dosage , Animals , Arterioles/drug effects , Arterioles/physiopathology , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Cyclic N-Oxides/pharmacology , Cyclooxygenase 2 , Dose-Response Relationship, Drug , Endothelin-1/pharmacology , Endothelins/metabolism , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Endothelium, Vascular/physiology , Isoenzymes/physiology , Male , Nitroarginine/pharmacology , Norepinephrine/pharmacology , Oxazoles/pharmacology , Oxidative Stress , Prostaglandin-Endoperoxide Synthases/physiology , Pyrazoles/pharmacology , RNA, Messenger/biosynthesis , Rabbits , Receptors, Thromboxane/antagonists & inhibitors , Receptors, Thromboxane/physiology , Spin Labels , Superoxides/metabolism , Vascular Resistance/drug effects
5.
J Am Soc Nephrol ; 14(11): 2775-82, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14569087

ABSTRACT

The hypothesis that a high salt (HS) intake increases oxidative stress was investigated and was related to renal cortical expression of NAD(P)H oxidase and superoxide dismutase (SOD). 8-Isoprostane PGF(2alpha) and malonyldialdehyde were measured in groups (n = 6 to 8) of conscious rats during low-salt, normal-salt, or HS diets. NADPH- and NADH-stimulated superoxide anion (O(2)(.-)) generation was assessed by chemiluminescence, and expression of NAD(P)H oxidase and SOD were assessed with real-time PCR. Excretion of 8-isoprostane and malonyldialdehyde increased incrementally two- to threefold with salt intake (P < 0.001), whereas prostaglandin E(2) was unchanged. Renal cortical NADH- and NADPH-stimulable O(2)(.-) generation increased (P < 0.05) 30 to 40% with salt intake. Compared with low-salt diet, HS significantly (P < 0.005) increased renal cortical mRNA expression of gp91(phox) and p47(phox) and decreased expression of intracellular CuZn (IC)-SOD and mitochondrial (Mn)-SOD. Despite suppression of the renin-angiotensin system, salt loading enhances oxidative stress. This is accompanied by increased renal cortical NADH and NADPH oxidase activity and increased expression of gp91(phox) and p47(phox) and decreased IC- and Mn-SOD. Thus, salt intake enhances generation of O(2)(.-) accompanied by enhanced renal expression and activity of NAD(P)H oxidase with diminished renal expression of IC- and Mn-SOD.


Subject(s)
Kidney Cortex/enzymology , NADH, NADPH Oxidoreductases/metabolism , Oxidative Stress/drug effects , Sodium Chloride, Dietary/administration & dosage , Superoxide Dismutase/metabolism , Animals , Dose-Response Relationship, Drug , Kidney Cortex/drug effects , Male , Models, Animal , NADH, NADPH Oxidoreductases/genetics , NADPH Oxidases , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Superoxide Dismutase/genetics
6.
J Am Soc Nephrol ; 14(11): 2783-9, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14569088

ABSTRACT

The hypothesis that O(2)(.-) enhances angiotensin II (AngII)-induced vasoconstriction and impairs acetylcholine-induced vasodilation of afferent arterioles (Aff) in AngII-induced hypertension was investigated. Rabbits (n = 6 per group) received 12 to 14 d of 0.154 M NaCl (Sham), subpressor AngII (60 ng/kg per min; AngII 60) or slow pressor AngII (200 ng/kg per min; AngII 200). Individual Aff were perfused in vitro at 60 mmHg. AngII 200 increased mean arterial pressure (mean +/- SD; 103 +/- 9 versus 73 +/- 6 mmHg; P < 0.01), plasma lipid peroxides (2.6 +/- 0.3 versus 2.0 +/- 0.3 nM; P < 0.05), renal cortical NADPH- and NADH-dependent O(2)(.-) generation, and Aff mRNA for p22(phox) 5-fold (P < 0.001) but decreased that for AT(1)-receptor 2.4-fold (P < 0.01). AngII 60 increased only NADH-dependent O(2)(.-) generation by renal cortex. Aff from AngII 200 rabbits had diminished acetylcholine relaxations (+50 +/- 4 versus +85 +/- 6%; P < 0.001), but these became similar in the presence of nitro-L-arginine (10(-4) M). Aff from AngII 60 and AngII 200 rabbits had unchanged norepinephrine contractions (10(-7) M) but significantly (P < 0.05) enhanced AngII contractions (10(-8) M: Sham -52 +/- 5 versus AngII 60 to 77 +/- 5 versus AngII 200 to 110 +/- 10%). The superoxide dismutase mimetic tempol (10(-4) M) moderated the AngII responses of Aff from AngII 200 rabbits to levels of AngII 60 rabbits (-64 +/- 7%). The AngII slow pressor response enhances renal cortical O(2)(.-) and p22(phox) expression. Increased O(2)(.-) generation in Aff mediates an impaired nitric oxide synthase-dependent endothelium-derived relaxing factor response and paradoxically enhances contractions to AngII despite downregulation of the mRNA for AT(1) receptors. A subpressor dose of AngII enhances Aff responses to AngII independent of O(2)(.-).


Subject(s)
Angiotensin II/administration & dosage , Kidney/blood supply , Kidney/metabolism , Oxidative Stress/physiology , Superoxides/metabolism , Vasoconstrictor Agents/administration & dosage , Afferent Pathways/blood supply , Afferent Pathways/drug effects , Animals , Arterioles/drug effects , Arterioles/metabolism , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Infusions, Parenteral , Kidney/drug effects , Male , Models, Animal , Rabbits , Reaction Time/drug effects
7.
Am J Physiol Regul Integr Comp Physiol ; 285(1): R117-24, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12609817

ABSTRACT

Oxidative stress accompanies angiotensin (ANG) II infusion, but the role of ANG type 1 vs. type 2 receptors (AT1-R and AT2-R, respectively) is unknown. We infused ANG II subcutaneously in rats for 1 wk. Excretion of 8-isoprostaglandin F2alpha (8-Iso) and malonyldialdehyde (MDA) were related to renal cortical mRNA abundance for subunits of NADPH oxidase and superoxide dismutases (SODs) using real-time PCR. Subsets of ANG II-infused rats were given the AT1-R antagonist candesartan cilexetil (Cand) or the AT2-R antagonist PD-123,319 (PD). Compared to vehicle (Veh), ANG II increased 8-Iso excretion by 41% (Veh, 5.4 +/- 0.8 vs. ANG II, 7.6 +/- 0.5 pg/24 h; P < 0.05). This was prevented by Cand (5.6 +/- 0.5 pg/24 h; P < 0.05) and increased by PD (15.8 +/- 2.0 pg/24 h; P < 0.005). There were similar changes in MDA excretion. Compared to Veh, ANG II significantly (P < 0.005) increased the renal cortical mRNA expression of p22phox (twofold), Nox-1 (2.6-fold), and Mn-SOD (1.5-fold) and decreased expression of Nox-4 (2.1-fold) and extracellular (EC)-SOD (2.1-fold). Cand prevented all of these changes except for the increase in Mn-SOD. PD accentuated changes in p22phox and Nox-1 and increased p67phox. We conclude that ANG II infusion stimulates oxidative stress via AT1-R, which increases the renal cortical mRNA expression of p22phox and Nox-1 and reduces abundance of Nox-4 and EC-SOD. This is offset by strong protective effects of AT2-R, which are accompanied by decreased expression of p22phox, Nox-1, and p67phox.


Subject(s)
Kidney/enzymology , NADPH Oxidases/metabolism , Oxidative Stress/physiology , Receptors, Angiotensin/metabolism , Superoxide Dismutase/metabolism , Angiotensin II/pharmacology , Angiotensin Receptor Antagonists , Animals , Antihypertensive Agents/pharmacology , Benzimidazoles/pharmacology , Biphenyl Compounds , Body Weight , Gene Expression Regulation, Enzymologic/drug effects , Gene Expression Regulation, Enzymologic/physiology , Imidazoles/pharmacology , Isoprostanes/pharmacology , Male , Malondialdehyde/metabolism , NADPH Oxidases/genetics , Pyridines/pharmacology , Rats , Rats, Sprague-Dawley , Receptor, Angiotensin, Type 1 , Receptor, Angiotensin, Type 2 , Superoxide Dismutase/genetics , Tetrazoles/pharmacology , Vasoconstrictor Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL